Measuring ROI in Medical Affairs

Measuring Return on Investment (ROI) in Medical Affairs (MA) is challenging because much of the value is intangible – knowledge generation, stakeholder relationships, and patient-impact, rather than direct sales. Unlike commercial teams, Medical Affairs teams focus on scientific exchange, education, and evidence generation. Thus, traditional ROI (financial gain/cost) does not capture their full value. Industry experts note that MA teams create “intangible value characterized by lengthy business cycles,” making it hard to track a clear financial return [1]. In practice, MA groups combine quantitative metrics (e.g., activities completed) with qualitative outcomes (e.g., insight quality, patient impact) to tell their ROI story [2][1]. Ultimately, ROI in Medical Affairs is often viewed as a multi-dimensional impact assessment: how well MA activities support strategy, enhance evidence, and improve patient outcomes, relative to resources invested.

Defining ROI for Medical Affairs

In a Medical Affairs context, ROI can mean more than dollars earned. Some experts even call it “return on intelligence,” emphasizing knowledge growth and strategic insights as success metrics [1]. Modern MA teams strive to align metrics with scientific and patient outcomes. For example, ROI might include successful completion of investigator-initiated trials, publications in peer-reviewed journals, changes in treatment guidelines, or improved patient access resulting from MA efforts. As one analysis notes, MA’s goal is ultimately to “improve patient care,” so patient outcomes (e.g., disease awareness, adherence, reduced diagnostic delays) can reflect the return on MA investment [3][1]. In short, ROI for MA is measured by how MA contributions advance clinical knowledge and patient health in proportion to cost and effort.

Because MA work is non-promotional, purely financial ROI formulas (profit minus cost) rarely apply. Instead, teams report a variety of performance metrics as proxies for ROI – both hard numbers and soft outcomes. Surveys of MA professionals find a tension between ease of measurement and strategic value. MA teams routinely report activity counts (numbers of KOL meetings, slide decks delivered, etc.), but recognize these do not capture real impact [2]. In one recent global survey, 92% of companies tracked simple activity metrics like key opinion leader (KOL) engagements, yet only 3% believed those metrics were “very effective” at reflecting true value [2]. Respondents overwhelmingly felt MA evaluation should shift toward more meaningful, impact-based measures [2].

Traditional Quantitative Metrics

Most companies still use quantitative metrics because they are easy to collect and report. Common numeric KPIs include:

• Engagement counts: Number of KOL/HCP interactions or advisory boards held.
• Publications and presentations: Number of abstracts/posters at congresses, peer-reviewed articles authored, or sponsored symposia.
• Educational programs: Number of medical education sessions delivered, slide decks or digital content assets produced.
• Coverage: Number of HCPs reached, geographic or therapeutic coverage, or email/newsletter distribution statistics.
• Response metrics: Inquiries answered by medical information, website visits or digital engagement rates, and training completions.

These measures show output (“how much MA did”) and can be tracked in dashboards. For example, one benchmarking report notes that MA dashboards often list totals of MSL interactions, insights collected, and publications as core outcomes [2]. Quantitative metrics can demonstrate activity levels and resource deployment. They are useful for internal management and for meeting compliance reporting requirements. However, they mainly reflect effort rather than impact. As one MA leader put it, activity KPIs “track the execution of the role, rather than their impact” [4].

Because quantitative metrics are straightforward, finance teams often use them to justify budgets. But industry studies warn that number-based ROI measures risk overlooking MA’s strategic contributions [2][1]. In fact, MA professionals themselves see a disconnect: while only 7% prefer purely quantitative evaluation, nearly all organizations continue to emphasize those metrics [2]. This misalignment explains why many MA teams call for new ROI approaches.

Qualitative and Outcome-based Metrics

To capture ROI more fully, Medical Affairs increasingly uses qualitative and outcome-oriented metrics alongside counts. These metrics aim to reflect real-world impact of MA activities. Key qualitative/outcome metrics include:

• Insight quality: Depth or novelty of clinical insights gathered from field engagements. For example, HCP feedback on unmet needs or the competitive landscape.
• KOL relationship strength: Assessment (often via surveys or interviews) of how trusted MA is with key experts. This might be scored by HCPs or through peer feedback.
• Stakeholder feedback: Direct feedback from healthcare providers or internal stakeholders on MA’s contributions. This could include surveys of how MA activities influenced clinical practice or organizational strategy.
• Evidence generation outcomes: Concrete results such as initiation of investigator-initiated trials, real-world evidence (RWE) studies opened, or patient registries started at MA’s instigation.
• Patient and public impact: Measures like increased patient awareness, improved adherence rates, or guideline changes. For instance, if an MA-led program helps get a new screening guideline adopted, that change is a high-level ROI.
• Time-to-decision gains: Reductions in the time required for formulary or regulatory decisions, attributable to MA data submissions.

Notably, a global survey found 70–67% of MA leaders want KPIs focusing on qualitative impact: quality of HCP relationships and value of insights gathered [2]. In practice, this means supplementing activity data with deeper narratives. For example, one company might report “through advisory boards, MA identified a clinical insight that became a co-authored publication,” tying the outcome back to specific activities [1]. Another may record KOL survey scores on how MA interactions influenced their prescribing confidence or clinical understanding.

Importantly, linking MA work to patient outcomes is emerging as the ultimate ROI metric. As the MSL journal notes, patient-centered outcomes (e.g., reduced hospitalizations, diagnostic rates) can serve as a “north star” for MA success [3]. While difficult to attribute directly, MA teams are exploring real-world data analytics to track these endpoints. For example, if MA educational efforts improve patient adherence by a measurable percentage, the resulting health gains and cost savings represent a valuable return.

Balanced Measurement Frameworks

Because no single metric captures MA’s full value, the best practice is a balanced, multidimensional framework [2][3]. Both recent studies and expert consensus emphasize combined quantitative and qualitative measures. For instance, MSL programs pair simple activity counts with outcomes-based measures like publications or clinical trial enrollments [1]. Indeed, a classic “MSL metrics consensus” advised that to validate a field team’s impact, companies should add qualitative and outcomes metrics to their scorecards [1]. Similarly, the 2024 MDPI survey concludes that MSL evaluation must integrate stakeholder feedback, insight quality, and strategic impact along with counts [2].

A practical framework might be a scorecard or KPI dashboard with multiple dimensions. For example:

• Activity (Quantitative): Number of HCP engagements, advisory boards, publications, and trainings (easy to tabulate).
• Engagement Quality (Qualitative): HCP survey ratings, depth-of-discussion scores, peer review of content.
• Outputs (Outcome): Research collaborations initiated, RWE studies launched, guidelines influenced, publications produced.
• Patient/Health Outcomes: Measures like adherence improvements, healthcare utilization changes, or patient experience surveys, where available.

By scoring performance across these axes, MA teams paint a richer ROI picture. Low-hanging fruits include adding short HCP surveys after events and tracking resulting leads (e.g., new trial proposals). For long-term ROI, teams may use medical CRM tools and analytics to connect engagement data with downstream indicators (e.g., linking an MSL call with a later protocol feasibility request).

Several organizations also develop value narratives to accompany metrics. In practice, MA often weaves qualitative ROI stories into reports: e.g., “MSLs identified a key clinical insight about patient subgroups; this led to a new post-market study that may support label expansion – a high-value outcome.” Such narratives bridge the gap between raw numbers and business outcomes.

Best Practices and Tools

To implement ROI measurement, Medical Affairs groups use a variety of tools and practices. Common elements include:

• Medical CRM/Dashboards: Centralized tracking of field activities, KOL interactions, and follow-ups. Dashboards can present both counts (e.g., visits) and outcomes (e.g., publications) side by side.
• Stakeholder Feedback Loops: Collect structured feedback from KOLs, physicians, and internal teams after major activities to assess perceived value.
• Analytics and AI: Leverage data science to analyze correlations between MA actions and outcomes (e.g., higher trial enrollment from active engagement regions). Social listening and sentiment analysis can even gauge HCP or patient reactions to MA-sponsored content.
• Insight Management Systems: Platforms for capturing and categorizing insights from the field, so MA can quantify “insights delivered” and tie them to strategy changes.
• Training on Metrics: Coaching MSLs and MA leaders on outcome-based thinking. The Chartered Institute suggests medical teams develop outcome-oriented KPIs rather than only counting calls.

Importantly, alignment with corporate objectives is critical. Leadership should agree on what “return” MA is expected to provide – whether that is accelerated R&D decisions, stronger payer positioning, or ultimate patient health gains. One expert advises that MA must learn to speak the “language of business strategy” when presenting impact [4]. By translating scientific successes into business terms (e.g., cost avoided, pipeline risk reduced, market differentiation) MA justifies its investments.

Conclusion

In summary, measuring ROI in Medical Affairs requires a holistic approach. MA teams blend quantitative KPIs with qualitative outcomes to demonstrate value. Recent research confirms that while organizations often default to counting activities, true ROI is reflected in deeper impacts—such as the quality of scientific exchange, stakeholder satisfaction, and ultimately, improvements in patient care [2][1]. Professionals certified through programs like Board Certified Medical Affairs Specialist (BCMAS) gain the skills to design and implement robust measurement frameworks, interpret complex data, and translate MA activities into strategic insights. This certification equips MA teams to use balanced scorecards and evidence-based narratives that align actions to organizational goals, ensuring that leadership recognizes the investment’s return not just in outputs, but in intelligence gained and lives improved.

References

[1] Chin, T., Weingard, S., & Knott, S. (2007). Metrics for Medical Science Liaisons: A Consensus Approach. Drug Information Journal, 41(3), 379–387. https://doi.org/10.1177/009286150704100311

[2] Tiwari, S., et al. (2024). Medical Affairs: Metrics and Performance Indicators—A Global Survey. Pharmaceuticals, 17(1), 84. https://doi.org/10.3390/ph17010084

[3] Vuong, Q., & Ho, T. (2023). Measuring Impact in Medical Affairs: From Activity to Outcomes. Journal of Medical Marketing, Advance online publication. https://doi.org/10.1177/17457904231150283

[4] Dyer, J. (2022). Communicating Value in Medical Affairs: Bridging Science and Business. Therapeutic Innovation & Regulatory Science, 56(5), 1051–1060. https://doi.org/10.1007/s43441-021-00370-3